Provided by Tiger Trade Technology Pte. Ltd.

FUNDX FUTURE FUND OPPORTUNITIES ETF

28.79
0.0000
Volume:6
Turnover:172.90
Market Cap:234.46M
PE:- -
High:28.79
Open:28.79
Low:28.79
Close:28.79
52wk High:31.30
52wk Low:25.44
Shares:8.15M
Float Shares:8.15M
Volume Ratio:0.00
T/O Rate:0.00%
Dividend:0.49
Dividend Rate:1.72%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Brazil's Central Bank Trims Rate to 13.75% as Tight Election Race Clouds Future Easing

Deep News
·
Sep 17

Halozyme Therapeutics Slips on $1.05 Bln Convertible Offering Plans

Reuters
·
Sep 17

Halozyme announces proposed offering of $1.05B of 2033 convertible senior notes

TIPRANKS
·
Sep 17

Halozyme Plans USD 1.05 Billion Convertible Senior Notes Offering Due 2033

Reuters
·
Sep 17

Halozyme Therapeutics, - Expects to Use Net Proceeds to Repurchase Outstanding 2027 and 2028 Convertible Notes

THOMSON REUTERS
·
Sep 17

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes Due 2033

THOMSON REUTERS
·
Sep 17

FireFox Gold Uncovers New High-Grade Lammas Zone at Mustajärvi Project in Finland

TIPRANKS
·
Sep 16

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Reuters
·
Sep 15

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS
·
Sep 15

Halozyme CEO Helen Torley Reports Disposal of Common Shares Worth USD 6.5 Million

Reuters
·
Sep 12

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live
·
Sep 09

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Dow Jones
·
Sep 08

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live
·
Sep 08

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live
·
Sep 08

Guardant Health initiated with a Buy at Rothschild & Co Redburn

TIPRANKS
·
Sep 08

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

TIPRANKS
·
Sep 05

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS
·
Sep 05

Analysts’ Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)

TIPRANKS
·
Sep 03